GlassScriptPhysician profile
Muhammad A Khan
NPI 1538348438
$2,636.48
in general payments reported to CMS, 2019-2025
26 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $54.12 · 2021: $133 · 2022: $492 · 2023: $432 · 2024: $632 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,129.87 | 2019-2025 | General - Pain Management |
| Abbott Laboratories | $477.92 | 2019-2025 | Proclaim |
| Medtronic, INC. | $150.45 | 2024-2025 | Intellis Adaptivestim |
| Nevro Corp. | $139.49 | 2019-2021 | |
| Abbvie INC. | $108.57 | 2021-2022 | |
| Saluda Medical Americas, INC. | $72.70 | 2024-2025 | Evoke |
| Depuy Synthes Sales INC. | $72.36 | 2019-2022 | |
| Curonix LLC | $51.51 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $45.46 | 2019 | |
| Fujifilm Sonosite, INC. | $38.21 | 2019 | |
| Bioventus LLC | $37.13 | 2025 | Gelsyn-3 |
| Averitas Pharma INC. | $34.80 | 2025 | Qutenza |
| Merck Sharp & Dohme LLC | $28.00 | 2021-2023 | Recarbrio, Dificid, Zerbaxa |
| Si-Bone, INC. | $27.39 | 2023 | |
| Medtronic USA, INC. | $26.96 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $26.28 | 2019-2020 | |
| Protega Pharmaceutials INC | $23.87 | 2025 | Roxybond |
| Kowa Pharmaceuticals America, INC. | $20.09 | 2022 | |
| Painteq LLC | $18.88 | 2023 | Painteq |
| Valinor Pharma, LLC | $18.68 | 2025 | Movantik |
| Amgen INC. | $18.09 | 2021 | |
| Vertos Medical, INC. | $16.67 | 2024 | Mild Device Kit |
| Insmed, INC. | $16.24 | 2022 | |
| Orthogenrx INC. | $14.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.83 | 2019 | |
| Forte Bio-Pharma LLC | $10.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.